直接抗病毒药物对儿童慢性丙型肝炎的治疗进展  

Progress of direct-acting antiviral agents in the treatment of children with chronic hepatitis C

作　　者：王福川 董漪 张敏 WANG Fu-chuan;DONG Yi;ZHANG Min(Center for Diagnosis,Treatment and Research of Adolescent Liver Diseases,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100039,China)

机构地区：[1]中国人民解放军总医院第五医学中心青少年肝病诊疗与研究中心

出　　处：《传染病信息》2019年第4期379-382,共4页Infectious Disease Information

摘　　要：聚乙二醇干扰素α-2a或α-2b联合利巴韦林是目前治疗儿童慢性丙型肝炎的标准方案。该方案最早应用于成人,对HCV的有效率仅约50%,并且对于儿童HCV的治疗有效率最高也只达70%。近年来,直接作用于HCV基因靶点的抗病毒药物(direct-acting antiviral agents,DAAs)不断被研发出来,对HCV的治疗起到质的飞跃,但该类药物在儿童HCV治疗中的应用大多处在临床试验阶段。本文通过对目前DAAs在儿童慢性丙型肝炎中的研究进展作一综述,以期为HCV患儿的临床治疗提供参考依据。Pegylated interferon alpha-2a or alpha-2b combined with ribavirin is the standard regimen for the treatment of children with chronic hepatitis C.This regimen is first applied to adults,and the effective rate to HCV is about 50%,the effective rate to HCV in children is only 70%.In recent years,many direct-acting antiviral agents(DAAs)directly targeting HCV genes have been developed and made great progress in treatment of HCV.The application of DAAs in the treatment of HCV among children is mostly at the stage of clinical trials.This article reviews the research progress of DAAs in children with chronic hepatitis C in order to provide reference for clinical treatment of children with HCV.

关 键 词：慢性丙型肝炎 儿童 直接抗病毒药物 

分 类 号：R512.63[医药卫生—内科学]